0001104659-25-110793 | 10-Q | XBRL Viewer

Print Document

Organization and Description of Business (Details) $ in Thousands		1 Months Ended			2 Months Ended	3 Months Ended		9 Months Ended
	Mar. 16, 2023 USD ($)	May 31, 2025 item	Dec. 31, 2024 USD ($) item	Apr. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)
Organization and Description of Business
Number of participants \| item		180	80
Accumulated deficit			$ 155,897			$ 207,372		$ 207,372
Net loss						18,040	$ 20,702	51,475	$ 38,778
Cash and cash equivalents			$ 176,498			$ 139,017		139,017
Proceeds from issuance of ordinary shares upon closing of business combination	$ 56,700
Aggregate sales price				$ 105,300	$ 75,800			$ 10,600

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Fair Value Measurements

9 Months Ended

Sep. 30, 2025

Fair Value Measurements

Fair Value Measurements

3.	Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis. The Company determines fair value based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. These levels are:

Level 1: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 2: Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

Level 3: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.

Financial instruments consist of cash and cash equivalents, prepaid and other current assets, accounts payable and accrued expenses, and private placement warrants. The carrying values of the Company’s cash, prepaid and other current assets, and accounts payable and accrued expenses approximate their fair value due to the short-term maturity of these instruments.

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024 (in thousands), and the fair value hierarchy of the valuation techniques utilized.


	September 30, 2025
	Level 1		Level 2		Level 3		Total
Financial assets:
Cash equivalents	$	135,905	$	—	$	—	$	135,905


	December 31, 2024
	Level 1		Level 2		Level 3		Total
Financial assets:
Cash equivalents	$	170,743	$	—	$	—	$	170,743

There were no transfers into or out of Level 1, Level 2, or Level 3 during the three and nine months ended September 30, 2025.

Private Placement Warrants

In August 2024, pursuant to the Warrant Exchange (as defined herein), the Company exchanged all of the outstanding Private Placement Warrants (as defined herein) for Class A Ordinary Shares. See Note 7. The Private Placement Warrants were measured at fair value on a recurring basis. Because the transfer of Private Placement Warrants to non-permitted transferees would result in the Private Placement Warrants having substantially the same terms as the Public Warrants (as defined herein), the Company determined that the fair value of each Private Placement Warrant is consistent with that of a Public Warrant. Accordingly, the Private Placement Warrants were classified as Level 2 financial instruments. Upon completion of the Warrant Exchange, the Private Placement Warrants were remeasured to settlement value which was determined based on the fair value of the Class A Ordinary Shares issued in exchange for the Private Placement Warrants. There were no Private Placement Warrants outstanding as of September 30, 2025 and December 31, 2024. The change in fair value of the Private Placement Warrants for the three and nine months ended September 30, 2024 was $3.9 million and $5.2 million, respectively.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2025	Nov. 10, 2025
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2025
Document Transition Report	false
Securities Act File Number	001-40598
Entity Registrant Name	ZURA BIO LIMITED
Entity Incorporation, State or Country Code	E9
Entity Tax Identification Number	98-1725736
Entity Address, Address Line One	1489 W. Warm Springs Rd. #110
Entity Address, City or Town	Henderson
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89014
City Area Code	702
Local Phone Number	825-9872
Title of 12(b) Security	Class A Ordinary Shares
Trading Symbol	ZURA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		65,023,308
Entity Central Index Key	0001855644
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q3
Amendment Flag	false

Share-based Compensation - Share option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2025	Dec. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Non market based PSO
Number of Options
Granted	408,000	1,053,000
Additional Information
Service period	1 year	1 year
Unrecognized share-based compensation expense		$ 1,500			$ 1,500
Equity Incentive Plan 2023
Number of Options
Beginning balance			12,217,747
Granted			5,715,390
Exercised			(75,468)
Forfeited			(1,038,270)
Ending balance		12,217,747	16,819,399		12,217,747
Options vested and exercisable			7,046,030
Weighted Average Exercise Price (per share)
Beginning balance			$ 2.88
Granted			1.2
Exercised			1.2
Forfeited			1.88
Ending balance		$ 2.88	2.38		$ 2.88
Options vested and exercisable			$ 2.27
Weighted Average Remaining Contractual Life (Years)
Options outstanding			8 years 7 months 6 days		8 years 10 months 24 days
Options vested and exercisable			8 years 1 month 6 days
Aggregate Intrinsic Value
Options outstanding		$ 8,388	$ 36,447		$ 8,388
Options vested and exercisable			$ 16,024
Additional Information
Weighted average grant date fair value			$ 0.97	$ 2.83
Outside of equity plan \| Directors Executives And Employees
Number of Options
Granted			2,055,314		2,165,369

Share-based Compensation (Details)			9 Months Ended
Share-based Compensation (Details)	Jan. 01, 2025 shares	Mar. 16, 2023 shares	Sep. 30, 2025 $ / shares shares	Sep. 30, 2024 $ / shares
Share-based Compensation
Share based payment award, option to vest (in years)		4 years
Expiration term (in years)		10 years
Maximum number of shares authorized			18,944,302
Equity Incentive Plan 2023
Share-based Compensation
Percentage of ordinary shares outstanding		5.00%
Maximum number of shares authorized		8,059,796
Number of options granted			5,715,390
Weighted-average assumptions used to estimate the fair value
Share price \| $ / shares			1.2	3.49
Expected volatility			1.003%	1.012%
Risk-free rate			0.041%	0.042%
Expected term (in years)			6 years 1 month 6 days	6 years 1 month 6 days
Expected dividend yield			0.00%	0.00%
Outside of equity plan
Share-based Compensation
Maximum number of shares authorized			2,055,314
Employee Stock Purchase Plan
Share-based Compensation
Maximum number of shares authorized		4,029,898
Percentage of discount for eligible employees		15.00%
Number of options granted			0
Shares available for grant under Equity Incentive Plan and ESPP \| Class A Ordinary shares
Share-based Compensation
Shares reserved for future issuances, increased percentage	5.00%
Shares reserved for future issuances, increased shares	3,264,877

License

9 Months Ended

Sep. 30, 2025

License

License

2023 Lilly License

On April 26, 2023, the Company’s consolidated subsidiary ZB17 LLC (“ZB17”) entered into a license agreement (the “2023 Lilly License” and, together with the 2022 Lilly License (as defined below), the “Lilly Licenses”) with Lilly, for an exclusive license to develop, manufacture and commercialize a certain bispecific antibody relating to IL-17 and BAFF (“tibulizumab”).

In 2023, in consideration for the investment made by Stone Peach, ZB17 granted Stone Peach the right, but not the obligation, to purchase 4.99% of the fully diluted equity of ZB17 for $1.0 million (the “Stone Peach Call Right”). The Stone Peach Call Right is not exercisable until after the last patient is dosed in any single next clinical trial with tibulizumab and expires one year from the date of first indication approval for tibulizumab by the FDA or the European Commission. The Stone Peach Call Right represents noncontrolling interest in the Company’s consolidated subsidiary, ZB17. As of September 30, 2025 and December 31, 2024, the noncontrolling interest balance was $1.5 million in the condensed consolidated balance sheets.

As additional consideration, beginning on May 1, 2023, Stone Peach receives an annual payment of $0.6 million initially, and increasing by 10% annually, so long as the Company maintains its license for tibulizumab, to be paid on May 1st of each year. The Company records expenses for these annual payments when they become due. An annual payment of $0.7 million was paid during each of the nine months ended September 30, 2025 and 2024. The Company recorded this payment within research and development expense in the condensed consolidated statement of operations.

A one-time payment of $4.5 million for additional consideration due to Stone Peach upon acceptance from the FDA for its Investigational New Drug (“IND”) and commencement of the clinical trial for tibulizumab was recorded in research and development in the consolidated statement of operations for the year ended December 31, 2024 and was paid in June 2025. The payment is included in accounts payable and accrued expenses in the condensed consolidated balance sheets as of December 31, 2024.

A letter agreement, dated as of April 25, 2023, by and between BAFFX17 Ltd (“BAFFX17”) and the Company, and as amended by Amendment No. 1 on December 18, 2023 (the “BAFFX17 Letter Agreement”), provided that, as a finder’s fee for arranging the acquisition of the 2023 Lilly License, the Company would be required to make a one-time milestone payment of $5.0 million to BAFFX17 upon the occurrence of either: (i) a change of control transaction, (ii) the closing of an issuance of equity or equity-linked securities by the Company of at least $100.0 million, (iii) the consummation of a sale of assets resulting in net proceeds in excess of $100.0 million, or (iv) the Company’s fully diluted shares outstanding exceed 52,500,000 shares (on a split adjusted basis) as measured on April 24^th of each year. As the Company’s fully diluted shares outstanding exceeded 52,500,000 shares prior to December 31, 2023, the $5.0 million fee was previously accounted for in research and development in the consolidated statement of operations for the year ended December 31, 2023, and is included in accounts payable and accrued expenses in the condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024. On June 30, 2025, the Company received an invoice on behalf of BAFFX17 requesting a $5.0 million milestone payment (the “Milestone Payment”) pursuant to the BAFFX17 Letter Agreement. The Company has not made such payment as of September 30, 2025.

In addition to the consideration paid and/or earned during the years ended December 31, 2024 and 2023, the Company is also obligated to make payments (a) to Lilly for four (4) development milestone payments up to an aggregate of $155.0 million, and sales milestone payments up to an aggregate of $440.0 million based on respective thresholds of net sales of products developed from tibulizumab; (b) to Lilly over a multi-year period (twelve years, or upon the later expiration of regulatory exclusivity of tibulizumab in a country) for an

annual earned royalty at a marginal royalty rate in the mid-single digits to low-double digits, with increasing rates depending on net sales in the respective calendar year, based on a percentage of sales within varying thresholds for a certain period of years; (c) to BAFFX17 for a fee equal to 3% of any milestone or royalty payments due to Lilly pursuant to the terms of either the 2022 Lilly License or the 2023 Lilly License; (d) to Stone Peach for a one-time milestone payment of $25 million upon either (i) certain equity-related transactions, or (ii) the receipt of regulatory approval from the applicable regulatory authority for any new indication in the applicable jurisdiction; and (e) to Stone Peach for a royalty of 2% of the aggregate net sales of any products developed from the Compound (collectively, the “2023 Lilly Contingent Payments”). As of September 30, 2025, none of the 2023 Lilly Contingent Payments are due and accordingly will not be recorded in the Company’s financial statements until they are due.

2022 Lilly License

On December 8, 2022, the Company’s consolidated subsidiary, Z33, entered into a license agreement (the “2022 Lilly License”) with Lilly pursuant to which Lilly granted Z33 an exclusive (even as to Lilly), royalty-bearing global license to develop, manufacture, and commercialize certain intellectual property owned by Lilly relating to its IL-33 compound.

A letter agreement dated as of December 8, 2022, as amended on November 21, 2023 (the “Stone Peach Letter Agreement”), by and between Stone Peach and the Company, provided that, as a finder’s fee for the 2022 Lilly License, the Company’s consolidated subsidiary Z33 issued 4,900,222 shares of Z33 Series Seed Preferred Shares to Stone Peach. Zura and Stone Peach have the following rights, as amended, (a) Zura had the right, but not the obligation to purchase up to 50% of the Series Seed Preferred Shares issued to Stone Peach at a price per share of $2.448869 for a period of two years from the date of the agreement (the “Call Option”); (b) Stone Peach has the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura for a price per share of $2.040724 (the “Put Option”), and (c) Stone Peach has the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura in exchange for 2,000,000 Class A Ordinary Shares (the “Put Right”). Stone Peach may exercise its Put Option and Put Right at any time between April 24, 2024, and April 24, 2028. See Note 10. The Z33 Series Seed Preferred Shares are remeasured to the greater of the redemption value or the initial fair value, less noncontrolling shareholder’s interest in net loss of Z33, at each reporting period. The Z33 Series Seed Preferred Shares represent redeemable noncontrolling interest in the Company’s consolidated subsidiary, Z33.

In July 2025, the Company received a request from Stone Peach to exercise the Put Option pursuant to which Stone Peach would sell 50% of its Series Seed Preferred Shares in Z33 for $5.0 million. Additionally, in July 2025, the Company received a further request from Stone Peach to exercise the Put Right pursuant to which Stone Peach would sell 50% of its Series Seed Preferred Shares in Z33 in exchange for 2,000,000 of the Company’s Class A Ordinary Shares. Upon exercise, the obligation to settle the Put Option in cash was recorded in accounts payable and accrued expenses and additional paid-in capital. As the Company has not yet made such cash payment, the obligation to settle the Put Right in Class A Ordinary Shares represents redeemable noncontrolling interest. As of September 30, 2025, $5.0 million to settle the Put Option is included in accounts payable and accrued expenses on the condensed consolidated balance sheet.

In addition to the consideration paid and transferred in 2022 and 2023, the Company is also obligated to make payments to Lilly for (a) $3.0 million upon the completion of a financing by Z33 with gross proceeds exceeding $100.0 million; (b) 10 commercial, development and regulatory milestone payments up to an aggregate of $155.0 million and sales milestone payments up to an aggregate of $440.0 million based on respective thresholds of net sales of products developed from the licensed compound, if any; and (c) an annual earned royalty at a marginal royalty rate between in the mid-single to low-double digits (less than 20%), with increasing rates based on net sales in the respective calendar year, based on a percentage of sales within varying thresholds for a certain period of the year, if any year (collectively, the “2022 Lilly Contingent Payments”). The Company will account for these contingent milestone payments when they become due. As of September 30, 2025, none of the 2022 Lilly Contingent Payments are due and accordingly will not be recorded in the Company’s financial statements until they are due. If a financing by Z33 with gross proceeds exceeding $100.0 million and corresponding payment of $3.0 million to Lilly does not occur by December 7, 2025, Lilly may terminate the 2022 Lilly License, unless by the same date, the Company makes a $3.0 million payment. As of September 30, 2025, no such payment has been made and will not be recorded in the Company’s financial statements until it is deemed probable.

Pfizer Agreement

On March 22, 2022, the Company entered into a license agreement and a Series A-1 Subscription and Shareholder’s Agreement (collectively, the “Pfizer Agreement”) with Pfizer. Under the Pfizer Agreement, the Company acquired a license for a compound previously developed by Pfizer.

In addition to the consideration paid and transferred during 2022 and 2023 and the first $1.0 million development milestone paid during 2024, the Company is obligated to make payments to Pfizer for (a) eleven (11) remaining future development and regulatory milestone payments aggregating up to $69.0 million and sales milestone payments up to an aggregate of $525.0 million based on respective thresholds of net sales of products (developed from the licensed compound) (the “Products”), if any; and (b) an annual earned royalty at a marginal royalty rate in the mid-single digits to low double digits (less than 20%), based on thresholds of net sales of the Company’s Products, if any (collectively, the “Pfizer Contingent Payments”). Royalties are payable on a country-by-country basis for a certain period of years or upon the later expiration of regulatory exclusivity of the Company’s Products in a country. As of September 30, 2025, no additional Pfizer Contingent Payments are due and accordingly no additional Pfizer Contingent Payments will be recorded in the Company’s financial statements until they are due.

Lonza License

In July 2022, the Company entered into a license agreement (the “Lonza License”) with Lonza Sales AG (“Lonza”) for a worldwide non-exclusive license for Lonza’s gene expression system in exchange for varying considerations depending on a number of factors such as whether the Company enters further into manufacturing agreements with Lonza or with a third party, and whether the Company enters into sublicense agreements with third parties (including up to middle six-figure annual payments per sublicense upon commencement of a sublicense, as well as royalties of up to low-single digit percentages of net sales of certain products over a commercially standard double-digit multi-year term). The Lonza License will remain in effect until terminated. The Company may terminate the Lonza License at any time upon 60 days’ notice, with or without cause. Lonza may terminate the Lonza License for cause upon a breach by the Company or for other commercially standard reasons.

Pursuant to the terms of the Lonza License, the Company has a license fee of $0.4 million due to Lonza annually in the fourth quarter as a result of manufacturing drug substance with a third party other than Lonza since 2023. For the year ended December 31, 2024, the Company recorded $0.4 million for the Lonza License, which is included in accounts payable and accrued expenses on the condensed consolidated balance sheet as of September 30, 2025 and December 31, 2024.

WuXi Biologics License

In July 2023, the Company entered into a biologics master services agreement (the “WuXi Biologics MSA”) with WuXi Biologics. Pursuant to the WuXi Biologics MSA, the parties enter into work orders setting forth the services and fees associated with drug substance and drug product activities and manufacturing for torudokimab, which fees are recognized as research and development expenses as incurred. Pursuant to the WuXi Biologics MSA, the Company entered into a cell line license agreement (the “Cell Line License Agreement”), which is further described below.

The Cell Line License Agreement was for certain of WuXi Biologics’ know – how, cell line, and biological materials (the “WuXi Biologics Licensed Technology”) to manufacture, have manufactured, use, sell and import certain products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the “WuXi Biologics Licensed Products”). If the Company manufactures all of its commercial supplies of bulk drug product for WuXi Biologics Licensed Products with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics in an amount equal to a fraction of a single digit percentage of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer (the “Royalty”). If the Company manufactures part of its commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. The Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company upon three months’ prior written notice and its payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a material breach by the Company that remains uncured for 30 days after written notice, or (iii) by WuXi Biologics if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure. As of September 30, 2025, there are no payments currently due under the Cell Line License Agreement.

Share-based Compensation

9 Months Ended

Sep. 30, 2025

Share-based Compensation

Share-based Compensation

8.	Share-based Compensation

On March 16, 2023, JATT’s board of directors approved the Zura Bio Limited 2023 Equity Incentive Plan (the “Equity Incentive Plan”) which became effective on the day immediately preceding the Closing Date of the Business Combination. The Equity Incentive Plan allows for the grant of share options, both incentive and nonqualified share options; stock appreciation rights (“SARs”), alone or in conjunction with other awards; restricted shares awards (“RSAs”) and restricted share units (“RSUs”); incentive bonuses, which may be paid in cash, shares, or a combination thereof; and other share-based awards to employees, officers, non-employee directors and other service providers. The Company has granted share options, RSUs and RSAs that generally vest over four years and expire after 10 years.

The Class A Ordinary Shares issuable under the Equity Incentive Plan are subject to an annual increase on January 1st of each calendar year beginning on January 1, 2024, and ending on and including January 1, 2029, equal to the lesser of (i) 5.0% of the aggregate number of Class A Ordinary Shares outstanding on the final day of the immediately preceding calendar year, (ii) 8,059,796 Class A Ordinary Shares or (iii) such smaller number of shares as is determined by the board.

On March 16, 2023, JATT’s board of directors approved the Zura Bio Limited 2023 Employee Share Purchase Plan (the “ESPP”) which became effective on the day immediately preceding the Closing Date of the Business Combination. The maximum number of Class A Ordinary Shares that may be issued under the ESPP is 4,029,898, plus an aggregate number of Class A Ordinary shares that are automatically added under the Equity Incentive Plan on January 1st of each calendar year, beginning on January 1, 2024, and ending on and including January 1, 2029, as discussed above. The ESPP enables eligible employees of the Company and designated affiliates to purchase Class A Ordinary Shares at a discount of 15%. As of September 30, 2025, the Company has not activated its ESPP.

On January 1, 2025, the Class A Ordinary Shares reserved for future issuances under the Equity Incentive Plan and/or ESPP were increased by the annual automatic increase of 5% of outstanding Class A Ordinary Shares as of December 31, 2024, or 3,264,877 Class A Ordinary Shares. As of September 30, 2025, there were 18,944,302 Class A Ordinary Shares authorized for issuance under the Equity Incentive Plan and ESPP, collectively, including 2,055,314 Class A Ordinary Shares authorized for issuance outside of the Equity Incentive Plan and the ESPP.

Equity Incentive Plan

Share Options

The fair value of Equity Incentive Plan share options are estimated on the date of grant using the Black-Scholes option pricing model. The Company lacks significant company-specific historical and implied volatility information. Therefore, it estimates its expected share volatility based on the historical volatility of a publicly traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company’s share options has been determined using the simplified method, averaging the vesting period and the contractual life of the share options granted. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

The following weighted-average assumptions were used to estimate the fair value of the Equity Incentive Plan share options issued during the nine months ended September 30, 2025 and 2024:


	For the Nine Months Ended
	September 30,
	2025			2024
Share price	$	1.20		$	3.49
Expected volatility		100.3	%		101.2	%
Risk-free rate		4.1	%		4.2	%
Expected term (in years)		6.1			6.1
Expected dividend yield		0	%		0	%

The following table summarizes the Company’s share option activity for the nine months ended September 30, 2025:


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise Price		Contractual	Value
	Options	(per share)		Life (Years)	(in thousands)
Options outstanding as of December 31, 2024	12,217,747	$	2.88	8.9	$	8,388
Granted	5,715,390	$	1.20
Exercised	(75,468)	$	1.20
Forfeited	(1,038,270)	$	1.88
Options outstanding as of September 30, 2025	16,819,399	$	2.38	8.6	$	36,447
Options vested and exercisable as of September 30, 2025	7,046,030	$	2.27	8.1	$	16,024

Included in options outstanding as of September 30, 2025 and December 31, 2024 in the table above are 2,055,314 and 2,165,369 options, respectively, to purchase Class A Ordinary Shares issued to certain directors, executives, and employees outside of the Equity Incentive Plan.

In May 2025, the Company granted 408,000 share options to purchase Class A Ordinary shares with non-market performance conditions (“PSOs”), included in the table above, that will vest upon the earlier of achieving a one-year service condition or upon the Company’s next Annual General Meeting (“AGM”).

In December 2024, the Company granted 1,053,000 PSOs (the “2024 PSOs”), included in the table above, that were to vest upon the earlier of achieving a one-year service condition or upon the Company’s AGM. In February 2025, the date of the AGM was set to May 21, 2025 (the “AGM Date”). Accordingly, management determined that the performance condition was met and recorded the remaining unrecognized compensation expense of $1.5 million ratably through the AGM Date. The 2024 PSOs vested on the AGM Date.

The weighted average grant date fair value of options granted during the nine months ended September 30, 2025 and 2024 was $0.97 and $2.83, respectively.

Market-Based Share Options

As of September 30, 2025, there are 306,373 options outstanding to purchase Class A Ordinary Shares, with market-based performance conditions, (“Market-Based Share Options”) that were granted to a certain director of the board during 2023. These awards will vest only to the extent that the 20-day volume weighted average trading price (“VWAP”) of the Class A Ordinary Shares is over $30 per Class A Ordinary Share at any time prior to the fifth anniversary of the grant date. These awards have an exercise price of $8.16 and become exercisable when vested and the market condition is satisfied. These awards expire 10 years from the date of grant. The fair value of these Market-Based Share Options was estimated using a Monte Carlo valuation method on the grant date. No Market-Based Share Options were granted during the nine months ended September 30, 2025 and the year ended December 31, 2024.

The expense recognized related to Market-Based Share Options was $0 and $0.2 million, respectively, for the three months ended September 30, 2025 and 2024, and $0.3 million and $0.5 million, respectively, for each of the nine months ended September 30, 2025 and 2024.

Restricted Share Units

The following table summarizes the Company’s RSU activity for the nine months ended September 30, 2025:



		Weighted
	Number of	Average
	RSUs	Grant Date FV
Unvested RSUs outstanding as of December 31, 2024	874,923	$	5.99
Released	(291,641)		5.99
Unvested RSUs outstanding as of September 30, 2025	583,282	$	5.99

The expense recognized related to RSUs was $0.5 million for each of the three months ended September 30, 2025 and 2024, and $1.3 million and $1.6 million for the nine months ended September 30, 2025 and 2024, respectively.

Restricted Share Awards

The following table summarizes the Company’s RSA activity for the nine months ended September 30, 2025:


		Weighted
		Average
	Number of	Grant Date
	RSAs	Fair Value
Unvested RSAs outstanding as of December 31, 2024	374,995	$	8.16
Vested	(124,998)		8.16
Unvested RSAs outstanding as of September 30, 2025	249,997	$	8.16

The expense recognized related to RSAs was $0.3 million for each of the three months ended September 30, 2025 and 2024, and $0.8 million for each of the nine months ended September 30, 2025 and 2024.

Equity Award Modification

During the three months ended June 30, 2025, the Company amended a member of the board of director’s option agreements, causing his unvested options to purchase 32,099 Class A Ordinary Shares to become fully vested and exercisable as of the AGM Date. Additionally, the board of directors extended the post-termination exercise period of his vested options to purchase an aggregate of 165,149 Class A Ordinary Shares to the applicable expiration date of each of the respective option awards, upon completion of his service as a member of the board of directors. During the nine months ended September 30, 2025, the Company recognized $0.1 million of share-based compensation expense related to this modification within general and administrative expense in the condensed consolidated statement of operations.

On June 27, 2025, the Company and Verender Badial, the Company’s former Chief Financial Officer, entered into an agreement in connection with Mr. Badial’s resignation from the Company (the “Settlement Agreement”). The Settlement Agreement provides for accelerated vesting of the unvested portion of two outstanding options, previously granted to Mr. Badial, relating to an aggregate of 198,540 Class A Ordinary Shares, which became fully vested and exercisable on July 31, 2025. The Settlement Agreement also provides for an extension of the post-termination exercise period of all of Mr. Badial’s vested share options to the applicable expiration date of

the applicable share option, as of July 31, 2025, subject to certain conditions therein. All other remaining unvested options to purchase Class A Ordinary Shares were forfeited and cancelled on July 31, 2025. For the three and nine months ended September 30, 2025, the Company recognized $0.1 million and $0.2 million, respectively, of share-based compensation expense related to this modification within general and administrative expense in the condensed consolidated statement of operations.

Share-based Compensation Expense

Share-based compensation expense for all equity arrangements for the three and nine months ended September 30, 2025 and 2024 was as follows (in thousands):


	For the Three Months Ended				For the Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
Research and development	$	569	$	772	$	1,463	$	1,841
General and administrative		1,810		7,874		8,292		12,140
Total share-based compensation expense	$	2,379	$	8,646	$	9,755	$	13,981

As of September 30, 2025, there was approximately $15.8 million of total unrecognized share-based compensation expense related to options granted to employees, executives, and directors that is expected to be recognized over a weighted average period of 3.0 years. As of September 30, 2025, there was approximately $2.9 million of total unrecognized share-based compensation expense related to RSUs granted to certain employees, executives, and directors under the Company’s Equity Incentive Plan that is expected to be recognized over a weighted average period of 1.7 years. As of September 30, 2025, there was approximately $1.5 million of total unrecognized share-based compensation expense related to RSAs granted to a certain director under the Company’s Equity Incentive Plan that is expected to be recognized over a weighted average period of 1.5 years.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2025

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial statements and include the accounts of its consolidated subsidiaries. Other shareholders’ interests in the Company’s subsidiaries, Z33 Bio, Inc. (“Z33”) and ZB17 LLC (“ZB17”), are shown in the condensed consolidated financial statements as redeemable noncontrolling interest and noncontrolling interest, respectively. All intercompany balances and transactions have been eliminated in consolidation.

These condensed consolidated financial statements are presented in accordance with the rules and regulations of the United States (“U.S.”) Securities and Exchange Commission (“SEC”) and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. As such, the information included herein should be read in conjunction with the Company’s consolidated financial statements and accompanying notes as of and for the year ended December 31, 2024 (the “audited consolidated financial statements”) that were included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 25, 2025 (the “Annual Report”). In Management’s opinion, these unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2025 and the results of operations for the three and nine months ended September 30, 2025 and 2024. The results of operations for the three and nine months ended September 30, 2025 are not necessarily indicative of the results to be expected for the full year ending December 31, 2025 or any other future interim or annual period.

Significant Accounting Policies

Except for the addition of Research and Development (“R&D”) incentive credits, there have been no significant changes in the Company’s significant accounting policies from those that were disclosed in Note 2, Summary of Significant Accounting Policies, included in the Company’s consolidated financial statements in the Company’s Annual Report.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the condensed consolidated financial statements relate to and include, but are not limited to, the fair value of share-based compensation, the fair value of redeemable noncontrolling interest, the valuation allowance of deferred tax assets resulting from net operating losses and the fair value of the private placement warrants.

Risks and Uncertainties

The Company is subject to risks common to early-stage companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from clinical manufacturing to commercial production of products.

The Company’s product candidates will require approvals from the United States Food and Drug Administration (“FDA”) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company.

The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.

Segments

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company’s CODM is the Chief Executive Officer or, when applicable, the Interim Chief Executive Officer. The Company and the CODM view its operations and manage its business as one operating segment, focused on developing novel medicines for immune and inflammatory disorders. The Company has business activities in different regions that are managed on a consolidated basis.

The accounting policies of the Company’s segment are the same as those described within this footnote. The CODM uses net loss, that is reported in the condensed consolidated statements of operations to assess performance for the Company’s segment and decide how to allocate resources. The significant expenses within net loss are separately presented in the Company’s condensed consolidated statement of operations. The CODM monitors budget versus actual results using operating loss which is a component of net loss. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets.

R&D Incentive Credits

The Company is eligible to obtain certain R&D incentive credits (the “R&D Credits”), through participation in the United Kingdom’s (“U.K.”) R&D Small and Medium Enterprise (“SME”) and the Research and Development Expenditure Credit (“RDEC”) tax relief programs.

The R&D Credits are calculated as a percentage of qualifying R&D expenses incurred as part of research projects. The R&D Credits are used as tax credits for the Company with the resulting amount being payable in cash by the U.K. government (tax authority) to the Company. The R&D Credits are subject to future audits by the U.K. tax authority within defined periods.

Although the incentive credits are administered through the local tax authority, the Company has accounted for the incentives outside of the scope of FASB Accounting Standards Codification Topic 740, Income Taxes (“ASC 740”), since the incentives are not linked to the Company’s taxable income and can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions. The Company accounts for these incentive credits as a government grant which analogizes with International Accounting Standards 20 (“IAS 20”), Accounting for Government Grants and Disclosure of Government Assistance.

In accordance with IAS 20, the Company will recognize the R&D Credits when it has reasonable assurance that the R&D Credits will be received. As the Company has only filed two claims under the tax relief programs as of September 30, 2025, it has determined that reasonable assurance will be met upon cash receipt. For the three and nine months ended September 30, 2025, the Company recorded $0.3 million in other income, net in the condensed consolidated statement of operations for R&D Credits received in May 2025. In April 2025, the Company filed an additional claim for an R&D Credit for $1.0 million that was not received as of September 30, 2025.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss attributable to Class A Ordinary Shareholders by the weighted-average number of Class A Ordinary Shares outstanding during the period. Basic and diluted net loss per share were the same for each period presented as the inclusion of all potentially dilutive securities outstanding would have been anti-dilutive due to the Company’s net loss.

The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as of the periods presented because to do so would be anti-dilutive:


	September 30,
	2025	2024
Shares issuable upon exercise of options to purchase Class A Ordinary Shares	14,480,663	9,318,906
Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right	2,000,000	2,000,000
Shares issuable upon vesting of restricted share units	573,282	1,050,720
Restricted share awards	249,997	374,995
Total	17,303,942	12,744,621

Income Taxes

On July 4, 2025, President Trump signed H.R. 1, the “One Big Beautiful Bill Act” (“OBBBA”) into law. The OBBBA makes permanent many of the provisions previously enacted as part of the 2017 Tax Cut and Jobs Act that were set to expire at the end of 2025 and includes other changes to certain U.S. corporate tax provisions including (i) the restoration of immediate expensing for domestic research and development expenditures, (ii) the reinstatement of 100% bonus depreciation for qualified property and (iii) favorably modifying the section 163(j) interest limitation (similar to EBITDA). FASB Topic 740, “Income Taxes”, requires the tax effects of changes in tax laws or rates be recognized in the period in which the law is enacted. The enactment of the OBBBA did not have a material impact on our effective tax rate as of September 30, 2025.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.

In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), ASU 2023-09 is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company beginning with the Company’s Annual Report on Form-10-K for the year ended December 31, 2025. Early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company’s consolidated financial statements and disclosures, but the Company expects considerable changes to the Company’s income tax disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). This ASU requires disclosure, in the notes to financial statements, of the nature of certain expenses included in the income statement. ASU 2024-03 will be effective for

annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2024-03 and expects to adopt it for the year ending December 31, 2027.

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Summary of Significant Accounting Policies

Schedule of potentially dilutive securities not included in calculation of diluted net loss per share because to do so would be anti-dilutive


	September 30,
	2025	2024
Shares issuable upon exercise of options to purchase Class A Ordinary Shares	14,480,663	9,318,906
Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right	2,000,000	2,000,000
Shares issuable upon vesting of restricted share units	573,282	1,050,720
Restricted share awards	249,997	374,995
Total	17,303,942	12,744,621

Shareholders' Equity - Ordinary Shares Reserved for Issuance (Details)	Sep. 30, 2025 shares
Shareholders' Equity
Shares reserved for issuance	47,273,048
Shares available for grant under 2023 Equity Incentive Plan and ESPP
Shareholders' Equity
Shares reserved for issuance	374,971
Shares issuable upon exercise of Z33 Put Right
Shareholders' Equity
Shares reserved for issuance	2,000,000
Shares issuable upon exercise of options to purchase Class A Ordinary Shares
Shareholders' Equity
Shares reserved for issuance	16,819,399
Shares issuable upon release of restricted share units
Shareholders' Equity
Shares reserved for issuance	583,282
Shares issuable upon exercise of pre-funded warrants to purchase Class A Ordinary Shares
Shareholders' Equity
Shares reserved for issuance	27,495,396

Condensed Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Shareholders' Equity - USD ($) $ in Thousands	Class A Ordinary Shares At The Market Offering	Class A Ordinary Shares April 2024 Private Placement	Class A Ordinary Shares Pre-Funded Warrants	Class A Ordinary Shares Private Placement Warrants	Class A Ordinary Shares Public warrants	Class A Ordinary Shares	Additional Paid-in Capital At The Market Offering	Additional Paid-in Capital April 2024 Private Placement	Additional Paid-in Capital Pre-Funded Warrants	Additional Paid-in Capital Private Placement Warrants	Additional Paid-in Capital	Accumulated Deficit	Noncontrolling interest	Redeemable Noncontrolling Interest	At The Market Offering	April 2024 Private Placement	Pre-Funded Warrants	Private Placement Warrants	Total
Balance at Dec. 31, 2023														$ 18,680
Redeemable Noncontrolling Interest
Adjustment of redeemable noncontrolling interest from redemption value to carrying value														(7,017)
Accretion of redeemable noncontrolling interest to redemption value														4,577					$ 4,577
Balance at Sep. 30, 2024														16,240
Beginning Balance (in shares) at Dec. 31, 2023						43,593,678
Balance at Dec. 31, 2023						$ 4					$ 162,820	$ (103,494)	$ 1,541						60,871
Increase (Decrease) in Stockholders' Deficit
Issuance of Class A ordinary shares	$ 1	$ 2					$ 5,533	$ 55,221							$ 5,534	$ 55,223
Issuance of Class A ordinary shares (in shares)	1,500,000	20,090,128
Issuance of Pre-Funded Warrants in exchange for Class A Ordinary Shares (in shares)			(4,000,000)
Issuance of Pre-Funded Warrants								$ 50,030								$ 50,030
Issuance of Class A Ordinary Shares in exchange of Warrants										$ 6,230								$ 6,230
Issuance of Class A Ordinary Shares in exchange of Warrants (in shares)				1,718,108	2,064,082
ATM transaction costs											(626)								(626)
Issuance of Class A Ordinary Shares for restricted share units, net of shares withheld for taxes											(318)								(318)
Issuance of Class A Ordinary Shares for restricted share units, net of shares withheld for taxes (in shares)						327,534
Share-based compensation											13,981								13,981
Accretion of additional paid in capital to redemption value											(4,577)								(4,577)
Adjustment of redeemable noncontrolling interest from redemption value to carrying value											7,017								7,017
Net loss												(38,778)							(38,778)
Ending Balance (in shares) at Sep. 30, 2024						65,293,530
Balance at Sep. 30, 2024						$ 7					295,311	(142,272)	1,541						154,287
Balance at Jun. 30, 2024														14,000
Redeemable Noncontrolling Interest
Accretion of redeemable noncontrolling interest to redemption value														2,240
Balance at Sep. 30, 2024														16,240
Beginning Balance (in shares) at Jun. 30, 2024						63,683,806
Balance at Jun. 30, 2024						$ 6					278,086	(121,570)	1,541						158,063
Increase (Decrease) in Stockholders' Deficit
Issuance of Class A ordinary shares	$ 1						5,533								5,534
Issuance of Class A ordinary shares (in shares)	1,500,000
Issuance of Pre-Funded Warrants in exchange for Class A Ordinary Shares (in shares)						(4,000,000)
Issuance of Class A Ordinary Shares in exchange of Warrants										$ 6,230								$ 6,230
Issuance of Class A Ordinary Shares in exchange of Warrants (in shares)				1,718,108	2,064,082
ATM transaction costs											(626)								(626)
Issuance of Class A Ordinary Shares for restricted share units, net of shares withheld for taxes											(318)								(318)
Issuance of Class A Ordinary Shares for restricted share units, net of shares withheld for taxes (in shares)						327,534
Share-based compensation											8,646								8,646
Accretion of additional paid in capital to redemption value											(2,240)								(2,240)
Net loss												(20,702)							(20,702)
Ending Balance (in shares) at Sep. 30, 2024						65,293,530
Balance at Sep. 30, 2024						$ 7					295,311	(142,272)	1,541						154,287
Balance at Dec. 31, 2024														11,663
Redeemable Noncontrolling Interest
Partial extinguishment of redeemable noncontrolling interest														(5,831)
Accretion of redeemable noncontrolling interest to redemption value														2,828					$ 2,828
Balance at Sep. 30, 2025														8,660
Beginning Balance (in shares) at Dec. 31, 2024						65,297,530													65,297,530
Balance at Dec. 31, 2024						$ 7					302,705	(155,897)	1,541						$ 148,356
Increase (Decrease) in Stockholders' Deficit
Issuance of Class A Ordinary Shares upon exercise of Pre-Funded Warrants			$ 1						$ 2								$ 3
Issuance of Class A Ordinary Shares upon exercise of Pre-Funded Warrants (Shares)			2,888,952
Issuance of Class A ordinary shares							$ 5,093								$ 5,093
Issuance of Class A ordinary shares (in shares)	3,000,000
Issuance of Pre-Funded Warrants in exchange for Class A Ordinary Shares (in shares)			(6,500,000)
Issuance of Pre-Funded Warrants in exchange for Class A Ordinary Shares			$ (1)						1
Issuance of Class A Ordinary Shares for share option exercises and restricted share units, net of shares withheld for taxes (Shares)						331,576
Issuance of Class A Ordinary Shares for share option exercises and restricted share units, net of shares withheld for taxes											49								49
Share-based compensation											9,755								9,755
Partial extinguishment of redeemable noncontrolling interest											831								831
Accretion of additional paid in capital to redemption value											(2,828)								(2,828)
Net loss												(51,475)							$ (51,475)
Ending Balance (in shares) at Sep. 30, 2025						65,018,058													65,018,058
Balance at Sep. 30, 2025						$ 7					315,608	(207,372)	1,541						$ 109,784
Balance at Jun. 30, 2025														11,663
Redeemable Noncontrolling Interest
Partial extinguishment of redeemable noncontrolling interest														(5,831)
Accretion of redeemable noncontrolling interest to redemption value														2,828
Balance at Sep. 30, 2025														$ 8,660
Beginning Balance (in shares) at Jun. 30, 2025						62,064,270
Balance at Jun. 30, 2025						$ 6					315,231	(189,332)	1,541						127,446
Increase (Decrease) in Stockholders' Deficit
Issuance of Class A Ordinary Shares upon exercise of Pre-Funded Warrants			$ (1)						$ (2)								$ (3)
Issuance of Class A Ordinary Shares upon exercise of Pre-Funded Warrants (Shares)			(2,888,952)
Issuance of Class A Ordinary Shares for restricted share units, net of shares withheld for taxes											(7)								(7)
Issuance of Class A Ordinary Shares for restricted share units, net of shares withheld for taxes (in shares)						64,836
Share-based compensation											2,379								2,379
Partial extinguishment of redeemable noncontrolling interest											831								831
Accretion of additional paid in capital to redemption value											(2,828)								(2,828)
Net loss												(18,040)							$ (18,040)
Ending Balance (in shares) at Sep. 30, 2025						65,018,058													65,018,058
Balance at Sep. 30, 2025						$ 7					$ 315,608	$ (207,372)	$ 1,541						$ 109,784

Fair Value Measurements (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2025	Dec. 31, 2024
Fair Value Measurements
Transfers between level 1 and level 2	$ 0	$ 0
Transfers level 2 and level 3	0	0
Transfers into or out of level 3	0	0
Cash equivalents \| Fair value recurring
Fair Value Measurements
Financial assets	135,905	135,905	$ 170,743
Level 1 \| Cash equivalents \| Fair value recurring
Fair Value Measurements
Financial assets	$ 135,905	$ 135,905	$ 170,743

Warrants (Details) - USD ($)			1 Months Ended			3 Months Ended	9 Months Ended
Warrants (Details) - USD ($)	Aug. 15, 2024	Aug. 12, 2024	Apr. 30, 2025	Apr. 30, 2024	Apr. 30, 2023	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Public warrants
Warrants
Number of warrants exchanged for shares		5,910,000
Private placement warrants
Warrants
Number of warrants exchanged for shares		6,899,996
Warrants outstanding						0		0
Pre-Funded Warrants
Warrants
Exercise Price	$ 0.001		$ 0.001			$ 0.001		$ 0.001
Number of warrants exchanged for shares	4,000,000		6,500,000
Warrants outstanding						27,495,396		23,884,348
Number of Class A ordinary shares upon exercise of each warrant	1
Notice period ( in days)	61 days
Pre-Funded Warrants \| Maximum
Warrants
Percentage of shares outstanding immediately prior to or after giving effect to exercise of share exchange	9.99%
Percentage of shares outstanding immediately after giving effect to exercise of share exchange	19.99%
Pre-Funded Warrants \| Minimum
Warrants
Percentage of shares outstanding immediately prior to or after giving effect to exercise of share exchange	4.99%
Pre-Funded warrants 2024
Warrants
Warrants outstanding						14,895,396
Pre-Funded warrants 2023
Warrants
Warrants outstanding						2,100,000
Class A Ordinary shares
Warrants
Number of shares surrendered	4,000,000		6,500,000
Consideration for shares surrendered	$ 0		$ 0
Class A Ordinary shares \| Public warrants
Warrants
Shares issued in exchange of warrants		2,064,082
Class A Ordinary shares \| Private placement warrants
Warrants
Shares issued in exchange of warrants		1,718,108
Class A Ordinary shares \| Pre-Funded warrants 2024
Warrants
Pre-Funded warrants, exercised						1,206,952
Class A Ordinary shares \| Pre-Funded warrants 2023
Warrants
Pre-Funded warrants, exercised						1,682,000
Private placement April 2023 \| Pre-Funded warrants 2023 \| Subscription Agreement
Warrants
Aggregate purchase price					$ 16,100,000
Private placement April 2023 \| Class A Ordinary shares \| Pre-Funded warrants 2023 \| Subscription Agreement
Warrants
Sale price per share					$ 4.249
Private placement April 2023 \| Class A Ordinary shares \| Pre-Funded warrants 2023 \| Subscription Agreement \| Maximum
Warrants
Number of warrants exchanged for shares					3,782,000
April 2024 Private Placement
Warrants
Aggregate purchase price							$ 55,223,000
April 2024 Private Placement \| Class A Ordinary shares \| Pre-Funded warrants 2024 \| Subscription Agreement
Warrants
Sale price per warrant				$ 3.107
Proceeds from sale of shares and warrants				$ 50,000,000
April 2024 Private Placement \| Class A Ordinary shares \| Pre-Funded warrants 2024 \| Subscription Agreement \| Maximum
Warrants
Number of warrants exchanged for shares				16,102,348

Redeemable Noncontrolling Interest (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	Dec. 08, 2022	Sep. 30, 2025	Sep. 30, 2025	Dec. 31, 2024
Redeemable Noncontrolling Interest
Accrued settlement of put option		$ 5,000	$ 5,000
Redeemable noncontrolling interest		$ 8,660	$ 8,660	$ 11,663
Stone Peach Properties, LLC \| Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right
Redeemable Noncontrolling Interest
Right but not the obligation to sell the issued shares, maximum percentage	50.00%
Remaining redeemable non-controlling interest percentage			50.00%
Stone Peach Properties, LLC \| Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right \| Put option
Redeemable Noncontrolling Interest
Percentage of redeemable non controlling interest		50.00%
Stone Peach Properties, LLC \| Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right
Redeemable Noncontrolling Interest
Number of shares transferred	4,900,222
Stone Peach Properties, LLC \| Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right \| Call option
Redeemable Noncontrolling Interest
Right but not the obligation for purchase of issued shares, maximum percentage	50.00%
Purchase price per share	$ 2.448869
Threshold period from the date of agreement for purchase of issued shares	2 years
Stone Peach Properties, LLC \| Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right \| Put option
Redeemable Noncontrolling Interest
Percentage of the call options exercised	50.00%
Selling price per share	$ 2.040724
Right but not the obligation to sell the issued shares, maximum percentage	50.00%
Stone Peach Properties, LLC \| Class A Ordinary shares
Redeemable Noncontrolling Interest
Number of shares in exchange for exercise of put Right	2,000,000

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
April 2024 Private Placement
Subsidiary, Sale of Stock [Line Items]
Issuance of shares, Transaction costs			$ 7.2
At The Market Offering
Subsidiary, Sale of Stock [Line Items]
Issuance of shares, Transaction costs	$ 0.2	$ 0.2	$ 0.2

Redeemable Noncontrolling Interest

9 Months Ended

Sep. 30, 2025

Redeemable Noncontrolling Interest

Redeemable Noncontrolling Interest

10.

Redeemable Noncontrolling Interest

As a finder’s fee for the 2022 Lilly License, the Company’s consolidated subsidiary Z33 issued 4,900,222 shares of Z33 Series Seed Preferred Shares to Stone Peach. Zura and Stone Peach have the following rights, as amended, (a) Zura had the right, but not the obligation to purchase up to 50% of the Series Seed Preferred Shares issued to Stone Peach at a price per share of $2.448869 for a period of two years from the date of the agreement (the “Call Option”); (b) Stone Peach has the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura for a price per share of $2.040724 (the “Put Option”), and (c) Stone Peach has the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura in exchange for 2,000,000 Class A Ordinary Shares (the “Put Right”). Stone Peach may exercise its Put Option and Put Right at any time between April 24, 2024, and April 24, 2028.

During the three months ended September 30, 2025, Stone Peach exercised its Put Option and Put Right. Upon exercise, the obligation to settle the Put Option in cash was recorded in accounts payable and accrued expenses extinguishing 50% of the redeemable noncontrolling interest. The Company has not yet made such payment. As of September 30, 2025, $5.0 million to settle the Put Option is included in accounts payable and accrued expenses on the condensed consolidated balance sheet. See Note 5.

As it is not possible to specifically identify the shares that may be redeemed upon exercising the Put Option, and the applicable unit of account is each share, the Company assessed that the remaining 50% of the Z33 Series Seed Preferred Shares must be considered redeemable until the settlement of the Put Option or Put Right. Accordingly, the 50% of the Z33 Series Seed Preferred Shares issued to Stone Peach represent redeemable noncontrolling interest and were remeasured as of September 30, 2025. As of September 30, 2025 and December 31, 2024, the redeemable noncontrolling interest balance was $8.7 million and $11.7 million, respectively.

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
Research and development	$ 11,948	$ 6,029	$ 31,126	$ 15,161
General and administrative	7,571	13,290	25,709	24,296
Total operating expenses	19,519	19,319	56,835	39,457
Loss from operations	(19,519)	(19,319)	(56,835)	(39,457)
Other (income)/expense, net:
Interest income	(1,526)	(2,461)	(5,060)	(5,872)
Change in fair value of private placement warrants		3,866		5,240
Other expense/(income), net	47	(22)	(300)	(47)
Total other (income)/expense, net	(1,479)	1,383	(5,360)	(679)
Loss before income taxes	(18,040)	(20,702)	(51,475)	(38,778)
Net loss	(18,040)	(20,702)	(51,475)	(38,778)
Accretion of redeemable noncontrolling interest to redemption value	(2,828)	(2,240)	(2,828)	(4,577)
Adjustment of redeemable noncontrolling interest	831		831	7,017
Net loss attributable to Class A Ordinary Shareholders of Zura	$ (20,037)	$ (22,942)	$ (53,472)	$ (36,338)
Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic (in dollars per share)	$ (0.21)	$ (0.26)	$ (0.57)	$ (0.52)
Net loss per share attributable to Class A Ordinary Shareholders of Zura, diluted (in dollars per share)	$ (0.21)	$ (0.26)	$ (0.57)	$ (0.52)
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic (in shares)	94,564,632	87,335,667	93,941,675	69,778,401
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, diluted (in shares)	94,564,632	87,335,667	93,941,675	69,778,401

License - 2023 Lilly License (Details)		9 Months Ended
License - 2023 Lilly License (Details)	Apr. 26, 2023 USD ($) payment shares	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) shares	Dec. 08, 2022 USD ($)
License
Noncontrolling interest balance		$ 1,541,000			$ 1,541,000
License agreement with Lilly
License
Maximum amount of development and regulatory milestone payments							$ 155,000,000
Maximum amount of sales milestone payments							$ 440,000,000
Contingent payments due		0
License agreement with Lilly \| BAFFX17, Ltd
License
Number of development and regulatory milestone payments \| payment	4
Maximum amount of development and regulatory milestone payments	$ 155,000,000
Maximum amount of sales milestone payments	$ 440,000,000
Period for payment of milestone payment	12 years
Percentage of royalty fee	3.00%
License agreement with Lilly \| Accounts Payable and Accrued Liabilities \| BAFFX17, Ltd
License
Minimum net proceeds from sale of assets for one-time milestone payment	$ 100,000,000
License agreement with Lilly \| Accounts Payable and Accrued Liabilities \| BAFFX17, Ltd
License
One-time milestone payment on achievement of conditions	5,000,000	0		$ 5,000,000		$ 5,000,000
Minimum value of closing of an issuance of equity for milestone payment	$ 100,000,000
Minimum fully diluted shares outstanding for milestone payment \| shares	52,500,000
Fully diluted shares exceeded the minimum limit for milestone payment \| shares						52,500,000
License agreement with Lilly \| Stone Peach Properties, LLC
License
One-time milestone payment					4,500,000
One-time milestone payment on achievement of conditions	$ 25,000,000
Percentage of royalty fee	2.00%
Contingent payments due		0
License agreement with Lilly \| Stone Peach Properties, LLC \| ZB17 LLC
License
Issued call right to purchase, percentage of fully-diluted equity	4.99%
Value of issued call right	$ 1,000,000
Expiry term from the date of regulatory approval milestone	1 year
Noncontrolling interest balance		1,500,000			$ 1,500,000
Annual amount of payment	$ 600,000
Percentage of annual increase in payment	10.00%
License agreement with Lilly \| Stone Peach Properties, LLC \| Research and development \| ZB17 LLC
License
Annual amount of payment		$ 700,000	$ 700,000

Shareholders' Equity

9 Months Ended

Sep. 30, 2025

Shareholders' Equity

Shareholders' Equity

6.	Shareholders’ Equity

On March 16, 2023, in connection with the closing of the Business Combination and effective upon the Closing Date, the Company authorized 300,000,000 Class A Ordinary Shares, par value of $0.0001 and 1,000,000 preferred shares, par value of $0.0001.

Exchange of Class A Ordinary Shares for Pre-Funded Warrants

In April 2025, the Company entered into share surrender and warrant agreements with certain affiliated shareholders (the “2025 Shareholders”), pursuant to which (i) the 2025 Shareholders surrendered an aggregate of 6,500,000 Class A Ordinary Shares owned by

the 2025 Shareholders, for no consideration, which were immediately cancelled and retired, upon surrender; and (ii) the Company issued pre-funded warrants to purchase an aggregate of 6,500,000 Class A Ordinary Shares (the “2025 Share Exchange Warrants) (such transaction, the “2025 Share Exchange”). See Note 7.

Shelf Registration and ATM Program

The Company filed a shelf registration statement on Form S-3 (the “Shelf Registration Statement”), which was declared effective on September 17, 2024. Pursuant to the Shelf Registration Statement, the Company may offer and sell ordinary shares, preference shares, debt securities, warrants and or units having an aggregate public offering price of up to $300.0 million. In connection with the filing of the Shelf Registration Statement, the Company also entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), relating to the sale of the Company’s Class A Ordinary Shares having an aggregate gross sales price of up to $125.0 million, from time to time through Leerink Partners, acting as sales agent (the “ATM”). During 2024, the Company incurred $0.6 million of offering expenses in connection with establishing the ATM.

During the nine months ended September 30, 2025, the Company sold 3,000,000 Class A Ordinary Shares at a price of $1.75 per share under the ATM, for net proceeds of $5.1 million, after sales agent commissions. During the three months ended September 30, 2025, there were no sales of Class A Ordinary Shares pursuant to the ATM. As of September 30, 2025, $114.0 million of Class A Ordinary Shares remained available for sale under the Sales Agreement.

Ordinary Shares Reserved for Issuance

A summary of shares reserved for issuance as of September 30, 2025 is summarized below:


		September 30, 2025
Shares issuable upon exercise of pre-funded warrants to purchase Class A Ordinary Shares		27,495,396
Shares issuable upon exercise of options to purchase Class A Ordinary Shares		16,819,399
Shares available for grant under 2023 Equity Incentive Plan and ESPP		374,971
Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right⁽¹⁾		2,000,000
Shares issuable upon release of restricted share units		583,282
Total shares reserved for issuance		47,273,048

(1) See Note 10 for more information.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2025

Commitments and Contingencies.

Commitments and Contingencies

9.	Commitments and Contingencies

Litigation

The Company is not a party to any material legal proceedings and is not aware of any material pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.

Summary of Significant Accounting Policies - R&D Incentive Credits (Details) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	Apr. 30, 2025 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2025 USD ($) claim
Summary of Significant Accounting Policies
Number of claims filed \| claim			2
R&D Credit	$ 1.0
Other Income
Summary of Significant Accounting Policies
R&D Credit		$ 0.3	$ 0.3

Accounts Payable and Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2025

Accounts Payable and Accrued Expenses

Schedule of accounts payable and accrued expenses

Accounts payable and accrued expenses is comprised of the following as of September 30, 2025 and December 31, 2024 (in thousands):


	September 30, 2025		December 31, 2024
Accrued research and development costs	$	8,632	$	7,100
Accrued 2023 Lilly License costs		5,000		9,500
Accrued settlement of Put Option		5,000		—
Accrued bonus		2,152		1,713
Accounts payable		3,275		733
Accrued professional fees		869		318
Other accrued expenses		563		150
Total accounts payable and accrued expenses	$	25,491	$	19,514

Share-based Compensation - Market-Based Performance Share Options (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 16, 2023	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Share-based Compensation
Expected life	10 years
Expense recognized		$ 2,379	$ 8,646	$ 9,755	$ 13,981
Market-Based Share Options
Share-based Compensation
Number of options outstanding		306,373		306,373
Period of volume weighted average trading price ("VWAP")				20 days
Minimum price per share for vesting awards				$ 30
Threshold period from grant date for vesting awards				5 years
Exercise price of shares granted				$ 8.16
Expected life				10 years
Number of options granted				0		0
Expense recognized		$ 0	$ 200	$ 300	$ 500

License (Details) $ in Millions		12 Months Ended
License (Details) $ in Millions	Mar. 22, 2022 USD ($) payment	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2025 USD ($)
Lonza milestone payment \| Research and development
License
Annual milestone payment, due and payable			$ 0.4
Lonza milestone payment \| Accounts Payable and Accrued Liabilities
License
Annual milestone payment, due and payable		$ 0.4
Wuxi Biologics License
License
Amount of license costs payable				$ 0.0
Agreement with Pfizer
License
Development Of research and development		$ 1.0
Number of development and regulatory milestone payments \| payment	11
Maximum amount of development and regulatory milestone payments	$ 69.0
Maximum amount of sales milestone payments	$ 525.0
Maximum annual earned royalty at a marginal royalty rate	20.00%
Amount of license costs payable				$ 0.0

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2025

Shareholders' Equity

Schedule of shares reserved for issuance


		September 30, 2025
Shares issuable upon exercise of pre-funded warrants to purchase Class A Ordinary Shares		27,495,396
Shares issuable upon exercise of options to purchase Class A Ordinary Shares		16,819,399
Shares available for grant under 2023 Equity Incentive Plan and ESPP		374,971
Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right⁽¹⁾		2,000,000
Shares issuable upon release of restricted share units		583,282
Total shares reserved for issuance		47,273,048

(1) See Note 10 for more information.

Defined Contribution Plans (Details) - USD ($)	3 Months Ended		9 Months Ended
Defined Contribution Plans (Details) - USD ($)	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Defined Contribution Plans
Employers matching contribution, annual vesting percentage			100.00%
Defined contribution plan expenses	$ 100,000	$ 57,000	$ 400,000	$ 200,000
Maximum \| US
Defined Contribution Plans
Matching contribution percent			6.00%
Maximum \| UK
Defined Contribution Plans
Matching contribution percent			6.00%

Summary of Significant Accounting Policies - Segments (Details)	9 Months Ended
	Sep. 30, 2025 segment
Summary of Significant Accounting Policies
Number of operating segments	1

Fair Value Measurements - Private Placement Warrants (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2025	Dec. 31, 2024
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Loss(Gain) from the change in fair value of the private placement warrants	$ 3,866	$ 5,240
Private placement warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Private Placement Warrants outstanding			0	0
Loss(Gain) from the change in fair value of the private placement warrants	$ 3,900	$ 5,200

Share-based Compensation (Tables)

9 Months Ended

Sep. 30, 2025

Share-based Compensation

Schedule of restricted share units



		Weighted
	Number of	Average
	RSUs	Grant Date FV
Unvested RSUs outstanding as of December 31, 2024	874,923	$	5.99
Released	(291,641)		5.99
Unvested RSUs outstanding as of September 30, 2025	583,282	$	5.99

Schedule of restricted share awards


		Weighted
		Average
	Number of	Grant Date
	RSAs	Fair Value
Unvested RSAs outstanding as of December 31, 2024	374,995	$	8.16
Vested	(124,998)		8.16
Unvested RSAs outstanding as of September 30, 2025	249,997	$	8.16

Schedule of share-based compensation expense


	For the Three Months Ended				For the Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
Research and development	$	569	$	772	$	1,463	$	1,841
General and administrative		1,810		7,874		8,292		12,140
Total share-based compensation expense	$	2,379	$	8,646	$	9,755	$	13,981

Equity Incentive Plan 2023

Share-based Compensation

Schedule of weighted-average assumptions used to estimate the fair value


	For the Nine Months Ended
	September 30,
	2025			2024
Share price	$	1.20		$	3.49
Expected volatility		100.3	%		101.2	%
Risk-free rate		4.1	%		4.2	%
Expected term (in years)		6.1			6.1
Expected dividend yield		0	%		0	%

Schedule of company's share option activity


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise Price		Contractual	Value
	Options	(per share)		Life (Years)	(in thousands)
Options outstanding as of December 31, 2024	12,217,747	$	2.88	8.9	$	8,388
Granted	5,715,390	$	1.20
Exercised	(75,468)	$	1.20
Forfeited	(1,038,270)	$	1.88
Options outstanding as of September 30, 2025	16,819,399	$	2.38	8.6	$	36,447
Options vested and exercisable as of September 30, 2025	7,046,030	$	2.27	8.1	$	16,024

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2025

Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

Significant Accounting Policies

Use of Estimates

Risks and Uncertainties

Segments

R&D Incentive Credits

Net Loss Per Share

The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as of the periods presented because to do so would be anti-dilutive:


	September 30,
	2025	2024
Shares issuable upon exercise of options to purchase Class A Ordinary Shares	14,480,663	9,318,906
Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right	2,000,000	2,000,000
Shares issuable upon vesting of restricted share units	573,282	1,050,720
Restricted share awards	249,997	374,995
Total	17,303,942	12,744,621

Income Taxes

Recently Issued Accounting Pronouncements

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2025

Fair Value Measurements

Schedule of financial assets and liabilities measured at fair value on a recurring basis


	September 30, 2025
	Level 1		Level 2		Level 3		Total
Financial assets:
Cash equivalents	$	135,905	$	—	$	—	$	135,905


	December 31, 2024
	Level 1		Level 2		Level 3		Total
Financial assets:
Cash equivalents	$	170,743	$	—	$	—	$	170,743

Condensed Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Shareholders' Equity (Parenthetical) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
April 2024 Private Placement
Subsidiary, Sale of Stock [Line Items]
Issuance of shares, Transaction costs			$ 7.2
At The Market Offering
Subsidiary, Sale of Stock [Line Items]
Issuance of shares, Transaction costs	$ 0.2	$ 0.2	$ 0.2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2025	Dec. 31, 2024
Condensed Consolidated Balance Sheets
Preferred shares, par value per share (in dollars per share)	$ 0.0001	$ 0.0001
Preferred shares authorized (in shares)	1,000,000	1,000,000
Preferred shares issued (in shares)	0	0
Preferred shares outstanding (in shares)	0	0
Class A ordinary shares, par value per share (in dollars per share)	$ 0.0001	$ 0.0001
Class A ordinary shares authorized (in shares)	300,000,000	300,000,000
Class A ordinary shares issued (in shares)	65,018,058	65,297,530
Class A ordinary shares outstanding (in shares)	65,018,058	65,297,530

Defined Contribution Plans

9 Months Ended

Sep. 30, 2025

Defined Contribution Plans

Defined Contribution Plans

11.

Defined Contribution Plans

The Company maintains a 401(k) defined contribution retirement plan (the “401(k) Plan”) for all of its U.S. employees. For the 401(k) Plan, the Company makes a matching contribution up to a maximum of 6% of an employee’s annual salary. For U.K. employees, the Company contributes up to 6% of an employee’s annual salary to defined contribution retirement pension plans (the “U.K. Defined Contribution Plan” and, together with the 401(k) Plan, the “Defined Contribution Plans”). Contributions made by the Company vest 100% upon contribution. The expense recorded for the Defined Contribution Plans was $0.1 million and $57,000 for the three months ended September 30, 2025 and 2024, respectively, and $0.4 million and $0.2 million for the nine months ended September 30, 2025 and 2024, respectively.

Warrants

9 Months Ended

Sep. 30, 2025

Warrants

Warrants

7.	Warrants

Pre-Funded Warrants

In April 2025, in conjunction with the 2025 Share Exchange (see Note 6), the Company issued the 2025 Share Exchange Warrants with an exercise price of $0.001 per share and no expiration date. The 2025 Share Exchange Warrants are exercisable immediately and have substantially identical terms to the form of 2024 Pre-Funded Warrant (see below).

On August 15, 2024, the Company entered into a share surrender and warrant agreement with certain affiliated shareholders (the “2024 Shareholders”), pursuant to which (i) the 2024 Shareholders surrendered an aggregate of 4,000,000 Class A Ordinary Shares owned by the 2024 Shareholders, for no consideration, which were immediately cancelled and retired, upon surrender; and (ii) the Company issued pre-funded warrants to purchase an aggregate of 4,000,000 Ordinary Shares, with an exercise price of $0.001 per share (the “2024 Share Exchange Warrants”).

In connection with the April 2024 Private Placement, the Company sold to accredited investors the pre-funded warrants to purchase up to 16,102,348 Class A Ordinary Shares at a price of $3.107 per pre-funded warrant for an aggregate purchase price of $50.0 million (the “2024 Pre-Funded Warrants”).

During the three months ended September 30, 2025, 1,206,952 Class A Ordinary Shares were issued in connection with the exercise of 2024 Pre-Funded Warrants. As of September 30, 2025, 14,895,396 of the 2024 Pre-Funded Warrants remained outstanding.

In connection with the April 2023 Private Placement, the Company sold to accredited investors pre-funded warrants to purchase up to 3,782,000 Class A Ordinary Shares at a price of $4.249 per pre-funded warrant for an aggregate purchase price of approximately $16.1 million (the “2023 Pre-Funded Warrants”).

During the three months ended September 30, 2025, 1,682,000 Class A Ordinary Shares were issued in connection with the exercise of 2023 Pre-Funded Warrants. As of September 30, 2025, 2,100,000 of the 2023 Pre-Funded Warrants remained outstanding.

As of September 30, 2025 and December 31, 2024, there was an aggregate 27,495,396 and 23,884,348 pre-funded warrants outstanding, respectively, consisting of the 2023 Pre-Funded Warrants, 2024 Pre-Funded Warrants, 2024 Share Exchange Warrants and the 2025 Share Exchange Warrants (collectively, the “Pre-Funded Warrants”), each with an exercise price of $0.001.

Each Pre-Funded Warrant is exercisable for one Class A Ordinary Share at any time or times until the Pre-Funded Warrants are exercised in full. A holder of the Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would beneficially own more than 4.99% or 9.99%, depending on the holder of the Company’s outstanding Class A Ordinary Shares immediately after exercise, which percentage may be increased or decreased to any other percentage specified not in excess of 19.99% at the holder’s election upon 61 days’ notice to the Company subject to the terms of the Pre-Funded Warrants.

Warrant Exchange

On August 12, 2024, the Company completed an exchange offer (the “Exchange Offer”) relating to its outstanding warrants that it assumed in connection with the Business Combination, including (i) public warrants to purchase 5,910,000 Class A Ordinary Shares (the “Public Warrants”) that were held by JATT, and (ii) private placement warrants to purchase 6,899,996 Class A Ordinary Shares (the “Private Placement Warrants”) that were held by JATT shareholders, and issued 2,064,082 Class A Ordinary Shares in exchange for the Public Warrants and 1,718,108 Class A Ordinary Shares in exchange for the Private Placement Warrants (collectively, the “Warrant Exchange”).

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 139,017	$ 176,498
Prepaid expenses and other current assets	3,275	2,246
Total current assets	142,292	178,744
Property and equipment, net	131	91
Other assets	1,512	698
Total assets	143,935	179,533
Current liabilities
Accounts payable and accrued expenses	25,491	19,514
Total current liabilities	25,491	19,514
Total liabilities	25,491	19,514
Commitments and contingencies (Note 9)
Redeemable noncontrolling interest	8,660	11,663
Shareholders' Equity
Preferred shares, $0.0001 par value, 1,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no shares issued and outstanding as of September 30, 2025 and December 31, 2024
Class A Ordinary Shares, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 65,018,058 and 65,297,530 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	7	7
Additional paid-in capital	315,608	302,705
Accumulated deficit	(207,372)	(155,897)
Total Zura Bio Limited shareholders' equity	108,243	146,815
Noncontrolling interest	1,541	1,541
Total shareholders' equity	109,784	148,356
Total liabilities, redeemable noncontrolling interest and shareholders' equity	$ 143,935	$ 179,533

Share-based Compensation - Equity Award Modification (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 27, 2025	May 31, 2025	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Share-based Compensation
Share-based compensation expense			$ 2,379	$ 8,646	$ 9,755	$ 13,981
Director
Share-based Compensation
Share-based compensation expense					100
Director \| Employee Stock Option \| Amendment of option agreements
Share-based Compensation
Share based payment award, options, vested, number of shares		32,099
Director \| Employee Stock Option \| Post-termination exercise period
Share-based Compensation
Share based payment award, options, vested, number of shares		165,149
Chief Financial Officer
Share-based Compensation
Share based payment award, options, vested, number of shares	198,540
Share-based compensation expense			$ 100		$ 200

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2025

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

4.	Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses is comprised of the following as of September 30, 2025 and December 31, 2024 (in thousands):


	September 30, 2025		December 31, 2024
Accrued research and development costs	$	8,632	$	7,100
Accrued 2023 Lilly License costs		5,000		9,500
Accrued settlement of Put Option		5,000		—
Accrued bonus		2,152		1,713
Accounts payable		3,275		733
Accrued professional fees		869		318
Other accrued expenses		563		150
Total accounts payable and accrued expenses	$	25,491	$	19,514

Organization and Description of Business

9 Months Ended

Sep. 30, 2025

Organization and Description of Business

Organization and Description of Business

1.	Organization and Description of Business

Zura Bio Limited, a Cayman Islands exempted company, formerly known as JATT Acquisition Corp (“JATT”), together with its subsidiaries (collectively, the “Company” or “Zura”), is a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases with unmet needs.

The Company’s strategic focus is to leverage dual-pathway biology to develop therapies intended to provide broader and deeper clinical benefits for patients with immune-mediated conditions. The Company currently has one clinical-stage product candidate in ongoing Phase 2 trials and is continuing to evaluate additional development opportunities within its pipeline, focusing on indications with unmet need and commercial potential.

The Company’s lead product candidate, tibulizumab (ZB-106), is an immunoglobulin G (“IgG”)-single-chain variable fragment (“scFv”) bispecific dual-antagonist antibody engineered by the fusion of TALTZ® (ixekizumab) and tabalumab to neutralize interleukin-17A (IL-17A) and B-cell activating factor (BAFF).

●

In May 2025, the Company initiated TibuSHIELD, a global randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating tibulizumab in approximately 180 adults with moderate to severe hidradenitis suppurativa (HS). The trial is designed to assess the safety, tolerability, and efficacy of tibulizumab for the treatment of HS in this patient population.

●

In December 2024, the Company initiated TibuSURE, a global randomized, double-blind, placebo-controlled Phase 2 study evaluating tibulizumab in approximately 80 adults with early diffuse cutaneous systemic sclerosis (dcSSc). The trial is designed to assess the safety, tolerability, and efficacy of tibulizumab for the treatment of dcSSc in this patient population.

Additionally, the Company is actively assessing the competitive landscape and evaluating potential therapeutic indications for crebankitug and torudokimab.

●

Crebankitug (ZB-168) is a fully human, high affinity monoclonal antibody that binds and neutralizes the interleukin-7 receptor (IL-7R) alpha chain. IL-7Rα sits at the nexus of two key immune pathways, IL-7 and thymic stromal lymphopoietin (“TSLP”), thus IL-7Rα has the potential to block activation through either of these pathways. As a result, the Company believes crebankitug could be therapeutically relevant in a broad set of indications where the IL-7 or TSLP pathways may be involved.

●

Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes interleukin-33 (“IL-33”), thereby inhibiting ST2-dependent inflammatory signaling and potentially modulating ST2-independent pathways, such as those mediated by the receptor for advanced glycation end products (“RAGE”). The IL-33/ST2 axis is supported by genetic evidence and is being investigated as a therapeutic target in inflammatory diseases, with development programs in asthma and ongoing evaluation in chronic obstructive pulmonary disease (“COPD”).

Business Combination

On March 20, 2023 (the “Closing Date”), the Company consummated the previously announced business combination (the “Business Combination”), pursuant to the terms of a business combination agreement (the “Business Combination Agreement”), dated as of June 16, 2022 (as amended on September 20, 2022, November 14, 2022, and January 13, 2023), by and among JATT, JATT Merger Sub, JATT Merger Sub 2, Zura Bio Holdings Ltd. (“Holdco”), and Zura Bio Limited, a limited company incorporated under the laws of England and Wales (“Legacy Zura”). Pursuant to the Business Combination Agreement, (a) before the closing of the Business Combination, Holdco was established as a new holding company of Legacy Zura and became a party to the Business Combination Agreement; and (b) on the Closing Date, in sequential order: (i) Merger Sub merged with and into Holdco, with Holdco continuing as the surviving company and a wholly owned subsidiary of JATT; (ii) immediately following the Merger, Holdco merged with and into Merger Sub 2, with Merger Sub 2 continuing as the surviving company and a wholly owned subsidiary of JATT; and (iii) JATT changed its name to “Zura Bio Limited”.

Prior to the Business Combination, JATT’s public shares, public warrants, and public units were listed on the New York Stock Exchange (“NYSE”) under the symbols “JATT,” “JATT.WS,” and “JATT.U,” respectively. On March 20, 2023, the Company’s Class A ordinary shares (“Class A Ordinary Shares”) and public warrants began trading on the Nasdaq Stock Market (“Nasdaq”) under the symbols “ZURA” and “ZURAW,” respectively. As of August 27, 2024, the Public Warrants (as defined herein) were no longer listed on the Nasdaq in connection with the completion of the Warrant Exchange (as defined herein). See Note 7.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the Company’s unaudited condensed consolidated financial statements (the “condensed consolidated financial statements”) may not be comparable to companies that comply with public company Financial Accounting Standards Board (“FASB”) standards’ effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an emerging growth company. The Company expects to no longer be an emerging growth company effective December 31, 2026.

Liquidity

The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The Company has an accumulated deficit of $207.4 million and $155.9 million as of September 30, 2025 and December 31, 2024, respectively, and a net loss of $18.0 million and $51.5 million for the three and nine months ended September 30, 2025, respectively. The Company’s existing sources of liquidity as of September 30, 2025 include $139.0 million in cash and cash equivalents.

Prior to the Business Combination, the Company historically funded operations primarily with issuances of convertible preferred shares and a promissory note. Upon the closing of the Business Combination, the Company received $56.7 million in net cash proceeds. Additionally, the Company raised (a) $10.6 million of cash proceeds after sales agent commissions in connection with sales under the ATM (as defined herein) since September 2024, (b) an aggregate of $105.3 million of net cash proceeds from the sale of Class A Ordinary Shares and pre-funded warrants in April 2024 (the “April 2024 Private Placement”), and (c) $75.8 million in net cash proceeds from the sale of Class A Ordinary Shares and pre-funded warrants in May and June 2023 (the “April 2023 Private Placement”). The Company’s cash requirements include, but are not limited to, clinical development, product manufacturing costs and working capital requirements. The Company expects that such operating losses and negative cash flows from operations will continue, but that it should have sufficient liquidity to fund its operations over the next twelve months.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Share-based Compensation - Restricted Share Units (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Weighted Average Grant Date Fair Value
Expense recognized	$ 2,379	$ 8,646	$ 9,755	$ 13,981
Shares issuable upon release of restricted share units
Number of RSUs
Beginning balance			874,923
Released			(291,641)
Ending balance	583,282		583,282
Weighted Average Grant Date Fair Value
Beginning balance			$ 5.99
Released			5.99
Ending balance	$ 5.99		$ 5.99
Expense recognized	$ 500	$ 500	$ 1,300	$ 1,600

Share-based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Share-based Compensation
Share-based compensation expense	$ 2,379	$ 8,646	$ 9,755	$ 13,981
Employee Stock Option
Share-based Compensation
Unrecognized share-based compensation expense	15,800		$ 15,800
Share-based compensation expense expected to be recognized over a weighted average period			3 years
Shares issuable upon release of restricted share units
Share-based Compensation
Share-based compensation expense	500	500	$ 1,300	1,600
Unrecognized share-based compensation expense	2,900		$ 2,900
Share-based compensation expense expected to be recognized over a weighted average period			1 year 8 months 12 days
Restricted share awards
Share-based Compensation
Share-based compensation expense	300	300	$ 800	800
Unrecognized share-based compensation expense	1,500		$ 1,500
Share-based compensation expense expected to be recognized over a weighted average period			1 year 6 months
Research and development
Share-based Compensation
Share-based compensation expense	569	772	$ 1,463	1,841
General and administrative
Share-based Compensation
Share-based compensation expense	$ 1,810	$ 7,874	$ 8,292	$ 12,140

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Cash flows from operating activities
Net loss		$ (51,475)	$ (38,778)
Adjustments to reconcile net loss before redeemable noncontrolling interest to net cash used in operating activities
Share-based compensation expense		9,755	13,981
Change in fair value of private placement warrants	$ 3,866		5,240
Depreciation and amortization		34	4
Foreign exchange transaction loss (gain)		73	(31)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(1,029)	283
Other assets		(814)
Accounts payable and accrued expenses		919	2,049
Net cash used in operating activities		(42,537)	(17,252)
Cash flows from investing activities
Purchase of property and equipment		(96)	(30)
Purchase of research and development license			(5,000)
Net cash used in investing activities		(96)	(5,030)
Cash flows from financing activities
Proceeds from exercise of share options		90
Proceeds from exercise of Pre-Funded Warrants		3
Payment of employee withholding taxes for restricted share units withheld		(34)
ATM transaction costs			(38)
Payment of deferred transaction costs			(52)
Net cash provided by financing activities		5,152	110,697
Net (decrease) increase in cash and cash equivalents		(37,481)	88,415
Cash and cash equivalents, beginning of period		176,498	99,806	$ 99,806
Cash and cash equivalents, ending of period	$ 188,221	139,017	188,221	176,498
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Partial extinguishment of redeemable noncontrolling interest		5,831
Accretion of redeemable noncontrolling interest to redemption value		2,828	4,577
Issuance of Class A Ordinary Shares in exchange for private placement warrants			6,230
Unpaid ATM transaction costs included in accounts payable and accrued expenses			588
Restricted share units withheld to pay employee withholding taxes that are included in accounts payable and accrued expenses		7	318
Adjustment of redeemable noncontrolling interest from redemption value to carrying value			7,017
Purchase of property and equipment included in accounts payable and accrued expenses		3	18
April 2024 Private Placement
Cash flows from financing activities
Proceeds from issuance of Class A Ordinary Shares in connection with April 2024 Private Placement, net of $7.2 million of transaction costs			55,223
Proceeds from issuance of Pre-Funded Warrants in connection with April 2024 Private Placement			50,030
At The Market Offering
Cash flows from financing activities
Proceeds from issuance of Class A Ordinary Shares in connection with a sale under the ATM, net of $0.2 million of commissions		$ 5,093	$ 5,534
ATM transaction costs				$ (600)

Summary of Significant Accounting Policies - Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Summary of Significant Accounting Policies
Total	17,303,942	12,744,621
Shares issuable upon exercise of options to purchase Class A Ordinary Shares
Summary of Significant Accounting Policies
Total	14,480,663	9,318,906
Shares issuable upon exercise of Z33 Put Right
Summary of Significant Accounting Policies
Total	2,000,000	2,000,000
Shares issuable upon vesting of restricted share units
Summary of Significant Accounting Policies
Total	573,282	1,050,720
Restricted share awards
Summary of Significant Accounting Policies
Total	249,997	374,995

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ (18,040)	$ (20,702)	$ (51,475)	$ (38,778)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Shareholders' Equity (Details) - USD ($)			1 Months Ended	9 Months Ended		12 Months Ended
Shareholders' Equity (Details) - USD ($)	Aug. 15, 2024	Mar. 16, 2023	Apr. 30, 2025	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024	Sep. 17, 2024
Shareholders' Equity
Class A ordinary shares authorized (in shares)		300,000,000		300,000,000		300,000,000
Class A ordinary shares, par value per share (in dollars per share)		$ 0.0001		$ 0.0001		$ 0.0001
Preferred shares, shares authorized		1,000,000		1,000,000		1,000,000
Preferred shares, par value per share (in dollars per share)		$ 0.0001		$ 0.0001		$ 0.0001
Transaction costs					$ 38,000
Proceeds from issuance of ordinary shares upon closing of business combination		$ 56,700,000
Pre-Funded Warrants
Shareholders' Equity
Number of warrants exchanged for shares	4,000,000		6,500,000
At The Market Offering
Shareholders' Equity
Aggregate amount of shares reserved				$ 114,000,000			$ 300,000,000
Transaction costs						$ 600,000
Proceeds from issuance of ordinary shares upon closing of business combination				$ 5,093,000	$ 5,534,000
Class A Ordinary shares
Shareholders' Equity
Number of shares surrendered	4,000,000		6,500,000
Consideration for shares surrendered	$ 0		$ 0
Class A Ordinary shares \| At The Market Offering
Shareholders' Equity
Aggregate amount of shares reserved							$ 125,000,000
Number of Class A shares issued				3,000,000
Price per share				$ 1.75

License - 2022 Lilly License (Details) - USD ($)			9 Months Ended
License - 2022 Lilly License (Details) - USD ($)	Jul. 14, 2025	Dec. 08, 2022	Sep. 30, 2025
License
Accrued settlement of put option			$ 5,000,000
Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right \| Put option
License
Put right percentage	50.00%
Consideration payable	$ 5,000,000
Class A Ordinary shares \| Put option
License
Shares of put option	2,000,000
Stone Peach Properties, LLC \| Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right
License
Number of shares transferred		4,900,222
Stone Peach Properties, LLC \| Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right \| Call option
License
Right but not the obligation for purchase of issued shares, maximum percentage		50.00%
Purchase price per share		$ 2.448869
Threshold period from the date of agreement for purchase of issued shares		2 years
Stone Peach Properties, LLC \| Shares issuable upon settlement of Z33 Series Seed Preferred Shares Put Right \| Put option
License
Right but not the obligation to sell the issued shares, maximum percentage		50.00%
Selling price per share		$ 2.040724
Stone Peach Properties, LLC \| Class A Ordinary shares \| Call option
License
Number of shares issued on exercise of call options		2,000,000
License agreement with Lilly
License
Amount of obligation to pay upon the completion of financing		$ 3,000,000	3,000,000
Minimum gross proceeds from financing for obligation to pay		100,000,000	100,000,000
Obligation to pay for retaining the license			3,000,000
Amount paid retaining the license			0
Maximum amount of development and regulatory milestone payments		155,000,000
Maximum amount of sales milestone payments		$ 440,000,000
Contingent payments due			0
Maximum annual earned royalty at a marginal royalty rate		20.00%
License agreement with Lilly \| Stone Peach Properties, LLC
License
Contingent payments due			$ 0

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Accounts Payable and Accrued Expenses
Accrued research and development costs	$ 8,632	$ 7,100
Accrued 2023 Lilly License costs	5,000	9,500
Accrued settlement of put option	5,000
Accrued bonus	2,152	1,713
Accounts payable	3,275	733
Accrued professional fees	869	318
Other accrued expenses	563	150
Total accounts payable and accrued expenses	$ 25,491	$ 19,514

Share-based Compensation - Restricted Share Awards (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Weighted Average Grant Date Fair Value
Expense recognized	$ 2,379	$ 8,646	$ 9,755	$ 13,981
Restricted share awards
Number of RSUs
Beginning balance			374,995
Vested			(124,998)
Ending balance	249,997		249,997
Weighted Average Grant Date Fair Value
Beginning balance			$ 8.16
Vested			8.16
Ending balance	$ 8.16		$ 8.16
Expense recognized	$ 300	$ 300	$ 800	$ 800